Work In Collaboration With Excellence

We have successfully recruited many industry-experienced scientists from across the globe to enrich and augment the drug hunting knowledgebase of our founding scientists. Our scientific teams are invariably highly qualified, and each program is allocated a project leader with relevant drug discovery experience. All are keen to collaborate with customers to achieve their shared goals. Our teams’ intellectual contribution is highly valued by our customers and recognised by co-authorship in numerous published patents assigned to and held by our customer companies.

Our experts specialise in eight key areas:

Targeted Protein Degradation

Targeted protein degradation is a novel drug discovery strategy being used to develop medicines aimed at so-called ‘undruggable’ proteins.

Hit Identification

Hit identification via screening services in a number of modes including fragment screening, virtual screening, phenotypic, high content and high throughput screening.

Lead Optimisation

Our highly efficient Lead Optimisation services are facilitated by the rapid generation of key in-vitro data to enable our scientists to design potent molecules with drug-like properties.

Structure-Based Drug Discovery

Whatever the origin of the hits, a structure-based approach can accelerate the enhancement of selectivity and potency during a multi-parameter lead optimisation process.

Target Validation

We provide a wide range of biochemical, biophysical and cell biology methodologies for target validation, target engagement and mode of action determination.

Hit-to-Lead

Sygnature Discovery is a premium provider of Hit to Lead services using its extensive expertise to assess screening hits and select the most suitable chemical series to develop.

Fragment Based Drug Discovery

Screening of our proprietary fragment library will provide low molecular weight hits that can be grown in a structure guided manner to deliver potent ligands with drug-like properties.

Route of Administration

We have successfully contributed to the development of many pre-clinical development compounds and investigational medicinal products (IMPs).

Hit Finding

Download our latest eBook

"Discovering and developing a new drug is a complex and time-consuming endeavour. Pharmaceutical and biotechnology companies are under tremendous pressure to be first to market. Yet, many of the best-validated targets are in challenging protein classes with little precedence for small molecule ligand binding. This creates a significant hurdle for hit finding. A carefully devised strategy is, therefore, essential when looking for validated hit series with a good chance of being developed into drug-like compounds."

Download

Delivering for our customers - a proven track record

  • 48 pre-clinical candidates delivered
  • 27 already progressed to clinical trials (>50%)
  • Sygnature Discovery co-inventors named on >170 client patent applications
Performance graph only (with atom filigrane)-1

Discover your next project's potential

Discover More